Main Article Content

Abstract

One of the medically important opportunistic fungal pathogen for humans is Candida glabrata that causes various types of candidiasis. Its environmental adaptations and antimicrobial resistance is now a great concern for public health. In the present study, the green tea phytocompounds; EGCg, Chlorogenic acid, Coumaroyl quinic acid and Rutin trihydrate along with a known antimycotic Fluconazole were studied for their antimycotic activity against Candida glabrata. The MIC90 for C. glabrata was observed at 125µg/ml for EGC g, 250 µg/mlf or Chlorogenic acid, 500µg/ml for Coumaroyl quinic acid and Rutin trihydrate while 12.5µg/ml for Fluconazole in macro dilution assay while the MFC values were 1000 µg/ml for EGC g, 500 µg/ml for Chlorogenic acid, Coumaroyl quinic acid, Rutin trihydrate and 50 µg/ml for Fluconazole. In microdilution assay, the MIC90 for C. glabrata was observed 125µg/ml for EGC g and chlorogenic acid, 500µg/ml for Coumaroyl quinic acid, Rutin trihydrate and 12.5µg/ml for Fluconazole while the MFC values were 31.25 µg/ml for Fluconazole, 250 µg/ml for chlorogenic acid and 500 µg/ml for EGC g, Coumaroyl quinic acid and Rutin trihydrate. EGCg and Chlorogenic acid was found to be more effective against C. glabrata and therefore these two were used for synergistic study along with Fluconazole. The viability of HeLa cells (in per cent) was observed ≥100% green tea phyto compounds. The viability of treated cells (in per cent) with a combination of Green tea, phytocompounds and fluconazole was observed between ≥98± 0.79 to ≥ 98± 0.87. Green tea phytocompounds mainly EGC g and chlorogenic acid can be used as synergistic molecules having antimycotic activity against C. glabrata.


 

Keywords

Antimycotic Activity Candida glabrata Green tea phytocompounds viability

Article Details

Author Biographies

Priyanka Sirari, Department of Biotechnology, Graphic Era Deemed to be University, Dehradun, Uttarakhand, India

 

 

Jigisha Anand, Department of Biotechnology, Graphic Era Deemed to be University, Dehradun, Uttarakhand, India

 

 

Manjusha Tyagi, Department of Microbiology, SGRR University, Dehradun, Uttarakhand, India

 

 

Rakesh Kuamar Bachheti, Department of Industrial Chemistry, College of Applied Science, Addis Ababa Science and Technology University, Addis Ababa, Ethiopia

 

 

Ashish Thapliyal, Department of Microbiology, Graphic Era Deemed to be University, Dehradun, Uttarakhand, India

 

 

How to Cite
Sirari, P., Anand, J., Tyagi, M., Bachheti, R. K., Thapliyal, A., & Rai, N. (2023). Antimycotic activity of green tea phytocompounds against Candida glabrata. Environment Conservation Journal, 24(3), 268–273. https://doi.org/10.36953/ECJ.26042341

References

  1. Aboody, M. S. A., & Mickymaray, S. (2020). Anti-Fungal Efficacy and Mechanisms of Flavonoids. Antibiotics (Basel, Switzerland), 9(2), 45. DOI: https://doi.org/10.3390/antibiotics9020045
  2. Anand J, Rai N, Kumar N, Gautam P. (2012). Green tea: a magical herb with miraculous outcomes. Int. Res. J. Pharm. 3(5): 139-148.
  3. Anand, J., & Rai, N. (2017). Anticandidal synergistic activity of green tea catechins, antimycotics and copper sulphate as a mean of combinational drug therapy against candidiasis. Journal de mycologie medicale, 27(1), 33–45. DOI: https://doi.org/10.1016/j.mycmed.2016.08.004
  4. Behbehani, J. M., Irshad, M., Shreaz, S., & Karched, M. (2019). Synergistic effects of tea polyphenol epigallocatechin 3-O-gallate and azole drugs against oral Candida isolates. Journal de mycologie medicale, 29(2), 158–167. DOI: https://doi.org/10.1016/j.mycmed.2019.01.011
  5. Cattaneo, L., Buonomo, A. R., Iacovazzo, C., Giaccone, A., Scotto, R., Viceconte, G., Mercinelli, S., Vargas, M., Roscetto, E., Cacciatore, F., Salvatore, P., Catania, M. R., Villari, R., Cittadini, A., Gentile, I., & Covid Federico Ii Team (2023). Invasive Fungal Infections in Hospitalized Patients with COVID-19: A Non-Intensive Care Single-Centre Experience during the First Pandemic Waves. Journal of fungi (Basel, Switzerland), 9(1), 86. DOI: https://doi.org/10.3390/jof9010086
  6. Chew, S. Y., Ho, K. L., Cheah, Y. K., Sandai, D., Brown, A. J. P., & Than, L. T. L. (2019). Physiologically Relevant Alternative Carbon Sources Modulate Biofilm Formation, Cell Wall Architecture, and the Stress and Antifungal Resistance of Candida glabrata. International journal of molecular sciences, 20(13), 3172. DOI: https://doi.org/10.3390/ijms20133172
  7. CLSI. (2002). M27-A2, Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-2nd Ed., vol.22, no.15.
  8. Fadeyi, S. A., Fadeyi, O. O., Adejumo, A. A., Okoro, C., & Myles, E. L. (2013). In vitro anticancer screening of 24 locally used Nigerian medicinal plants. BMC complementary and alternative medicine, 13, 79. DOI: https://doi.org/10.1186/1472-6882-13-79
  9. Gómez-Gaviria, M., Ramírez-Sotelo, U., & Mora-Montes, H. M. (2022). Non-albicans Candida Species: Immune Response, Evasion Mechanisms, and New Plant-Derived Alternative Therapies. Journal of fungi (Basel, Switzerland), 9(1), 11. https://doi.org/10.3390/jof9010011 DOI: https://doi.org/10.3390/jof9010011
  10. Haghjoo, B., Lee, L.H., Habiba, U., Tahir, H., Olabi, M.M., & Chu, T. (2013). The synergistic effects of green tea polyphenols and antibiotics against potential pathogens. Advances in Bioscience and Biotechnology, 4, 959-967. DOI: https://doi.org/10.4236/abb.2013.411127
  11. Haji, M.H., Mohamed, A.B., Albashir, A.A., & Mirghani, M.E. (2022). A Review of Antifungal Activity of Combined Plant Extracts or Plant Exudates from Medicinal Plants either together or with Known Antifungal Agents. European Journal of Medicinal Plants. DOI: https://doi.org/10.9734/ejmp/2022/v33i830483
  12. Hirasawa, M., & Takada, K. (2004). Multiple effects of green tea catechin on the antifungal activity of antimycotics against Candida albicans. The Journal of antimicrobial chemotherapy, 53(2), 225–229. DOI: https://doi.org/10.1093/jac/dkh046
  13. Jin, J., Guo, N., Zhang, J., Ding, Y., Tang, X., Liang, J., Li, L., Deng, X., & Yu, L. (2010). The synergy of honokiol and fluconazole against clinical isolates of azole-resistant Candida albicans. Letters in applied microbiology, 51(3), 351–357.https://doi.org/10.1111/j.1472-765X.2010.02900.x DOI: https://doi.org/10.1111/j.1472-765X.2010.02900.x
  14. Kane, A., & Carter, D. A. (2022). Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox. Pharmaceuticals (Basel, Switzerland), 15(4), 482. DOI: https://doi.org/10.3390/ph15040482
  15. Kaya, E.G., & Ozbilge, H. (2012). Determination of the effect of fluconazole against Candida albicans and Candida glabrata by using microbroth kinetic assay*. Turkish Journal of Medical Sciences. DOI: https://doi.org/10.3906/sag-1010-1211
  16. Kováč, J., Slobodníková, L., Trajčíková, E., Rendeková, K., Mučaji, P., Sychrová, A., & Bittner Fialová, S. (2022). Therapeutic Potential of Flavonoids and Tannins in Management of Oral Infectious Diseases-A Review. Molecules (Basel, Switzerland), 28(1), 158. DOI: https://doi.org/10.3390/molecules28010158
  17. Kumar, K., Askari, F., Sahu, M. S., & Kaur, R. (2019). Candida glabrata: A Lot More Than Meets the Eye. Microorganisms, 7(2), 39. DOI: https://doi.org/10.3390/microorganisms7020039
  18. Lionakis, M. S., Drummond, R. A., & Hohl, T. M. (2023). Immune responses to human fungal pathogens and therapeutic prospects. Nature reviews. Immunology, 23(7), 433–452. https://doi.org/10.1038/s41577-022-00826-w DOI: https://doi.org/10.1038/s41577-022-00826-w
  19. Lu, M., Li, T., Wan, J., Li, X., Yuan, L., & Sun, S. (2017). Antifungal effects of phytocompounds on Candida species alone and in combination with fluconazole. International journal of antimicrobial agents, 49 2, 125-136. DOI: https://doi.org/10.1016/j.ijantimicag.2016.10.021
  20. Marchetti, O., Moreillon, P., Glauser, M.P., Billé, J., & Sanglard, D. (2000). Potent Synergism of the Combination of Fluconazole and Cyclosporine in Candida albicans. Antimicrobial Agents and Chemotherapy, 44, 2373 - 2381. DOI: https://doi.org/10.1128/AAC.44.9.2373-2381.2000
  21. Pais, P., Galocha, M., Viana, R., Cavalheiro, M., Pereira, D., & Teixeira, M.C. (2019). Microevolution of the pathogenic yeasts Candida albicans and Candida glabrata during antifungal therapy and host infection. Microbial Cell, 6, 142 - 159. DOI: https://doi.org/10.15698/mic2019.03.670
  22. Patel, LR., JD, Pethani., P, Bhatia., SD, Rathod., P.D, Shah. (2012). Prevalence of Candida infection and its antifungal susceptibility pattern in tertiary care hospital, Ahmedabad. Nat J Med Res. 2: 439-441. DOI: https://doi.org/10.15373/22778179/MAR2013/97
  23. Pfaller, M. A., Diekema, D. J., Procop, G. W., & Rinaldi, M. G. (2007). Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. Journal of clinical microbiology, 45(11), 3522–3528. DOI: https://doi.org/10.1128/JCM.00403-07
  24. Radji, M., Agustama, R. A., Elya, B., & Tjampakasari, C. R. (2013). Antimicrobial activity of green tea extract against isolates of methicillin-resistant Staphylococcus aureus and multi-drug resistant Pseudomonas aeruginosa. Asian Pacific journal of tropical biomedicine, 3(8), 663–666. https://doi.org/10.1016/S2221-1691(13)60133-1 DOI: https://doi.org/10.1016/S2221-1691(13)60133-1
  25. Singh, RI., I, Xess., P, Mathur., B, Behera., B, Gupta., M C, Misra. (2011). Epidemiology of candidaemia in critically ill trauma patients: experiences of a level I trauma centre in North India. J Med Microbiol. 60: 342-348. DOI: https://doi.org/10.1099/jmm.0.023739-0
  26. Sirari, P., Anand, J., Devvret, Thapliyal, A & Rai, N. (2021). Green tea phytocompounds targets Lansterol 14-α demethylase against ergosterol biosynthesis in Candida glabrata. International Journal of Research in Pharmaceutical Sciences, 12(3), 1793–1797. Retrieved from https://ijrps.com/home/article/view/304 DOI: https://doi.org/10.26452/ijrps.v12i3.4840
  27. Yapar, N. (2014). Epidemiology and risk factors for invasive candidiasis. Therapeutics and clinical risk management, 10, 95–105. DOI: https://doi.org/10.2147/TCRM.S40160